Harrow Health Charts Aggressive Growth Path with Sales Overhaul and Brand Consolidation

Harrow Health has reaffirmed its ambitious financial targets for 2025, outlining a comprehensive strategy centered on a major sales force expansion and a unified branding initiative. The company's plan aims to significantly boost its commercial footprint, raising questions about the efficacy of its new "OneHarrow" approach in driving revenue.

• Confirmed 2025 revenue forecast remains at $270 to $280 million.
• Sales teams for core products VEVYE and TRIESENCE are slated to double in size.
• The "OneHarrow" initiative consolidates all product lines under a single, central brand identity.

A cornerstone of the growth plan involves doubling the sales team dedicated to the drug VEVYE. The objective is to cover approximately 100 U.S. sales territories by the end of May 2026. This expansion is supported by an improved reimbursement landscape through pharmacy benefits, which took effect on January 1, 2026. A parallel doubling of the surgical sales force for TRIESENCE is also underway. For IHEEZO, the company is concentrating on the in-office procedure market, estimated to encompass 2.5 million annual procedures.

Supporting this commercial push, Harrow Health has promoted Patrick W. Sullivan to the role of Chief Commercial Officer. Sullivan, who originally joined the firm in August 2025, is now tasked with enhancing the efficiency of all market-facing operations.

Strategic Integration and Pipeline Development

The "OneHarrow" strategy represents a significant organizational shift, bringing all product lines—including compounded pharmaceuticals—under one cohesive structure. This rebranding and consolidation effort is designed to streamline commercial efforts.

Should investors sell immediately? Or is it worth buying Harrow Health?

Concurrently, management is advancing the integration of Melt Pharmaceuticals, which was acquired in November 2025. The company is preparing to submit regulatory filings for its non-opioid sedation therapies, MELT-300 and MELT-210, in the first half of 2027.

On the regulatory front, the ImprimisRx division has concluded a chapter of legal proceedings. Following the settlement of disputes with California authorities, Harrow withdrew from the state's compounding pharmacy market effective February 1, 2026.

Early Indicators and Forthcoming Results

The company's strategic moves are beginning to yield early signs of traction. Prescription volumes for VEVYE demonstrated a consistent month-over-month increase throughout January 2026.

Investors can expect a detailed financial update in the near future. Harrow Health is scheduled to release its fourth-quarter and full-year 2025 results around March 16 or 26, 2026.